The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients

scientific article published on 8 September 2008

The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1001077473
P356DOI10.1186/1742-4690-5-78
P932PMC publication ID2563025
P698PubMed publication ID18778482
P5875ResearchGate publication ID23244328

P50authorNuno TaveiraQ42305919
Francisco AntunesQ43153431
Perpétua GomesQ54603815
Helena BarrosoQ55302937
Pedro BorregoQ56854274
Cheila RochaQ56854288
José Maria MarcelinoQ56975479
Carlos NovoQ57447046
P2093author name stringFernando Maltez
Manuela Doroana
P2860cites workThe causes and consequences of HIV evolutionQ22251040
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis toolsQ24248165
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infectionQ24538985
Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infantQ24815687
Role of viral evolutionary rate in HIV-1 disease progression in a linked cohortQ24815853
Confidence Limits on Phylogenies: an Approach using the BootstrapQ26778379
MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) Software Version 4.0Q26778434
MODELTEST: testing the model of DNA substitutionQ26778437
Evolutionary trees from DNA sequences: A maximum likelihood approachQ27860898
Human immunodeficiency virus type 2Q28218992
Reduced rate of disease development after HIV-2 infection as compared to HIV-1Q28237927
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutininQ28264707
HyPhy: hypothesis testing using phylogeniesQ29013475
Antibody neutralization and escape by HIV-1Q29547345
Rapid evolution of the neutralizing antibody response to HIV type 1 infectionQ29618603
Structure of a V3-containing HIV-1 gp120 coreQ29619014
Unifying the epidemiological and evolutionary dynamics of pathogensQ29619092
Slower heterosexual spread of HIV-2 than HIV-1.Q30419674
Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelopeQ33269794
Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamicsQ33274194
Virological and molecular demonstration of human immunodeficiency virus type 2 vertical transmissionQ33783504
Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of new discontinuous epitopesQ33803939
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infectionQ33825654
HIV evolutionary dynamics within and among hostsQ34000621
Use of a new dual-antigen enzyme-linked immunosorbent assay to detect and characterize the human antibody response to the human immunodeficiency virus type 2 envelope gp125 and gp36 glycoproteinsQ34430673
Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individualsQ34437201
Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivityQ35101464
Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infectionQ35185919
Identifying epitopes of HIV-1 that induce protective antibodiesQ35708836
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispeciesQ35784605
Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infectionsQ35857480
Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infectionQ35857567
N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with changes in antibody recognition of the V1/V2 region of gp120Q35870879
Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDSQ35895520
Evolutionary mechanisms and population dynamics of the third variable envelope region of HIV within single hostsQ35994354
The c3-v4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infectionQ36483346
Improving on nature: focusing the immune response on the V3 loop.Q36487155
Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell declineQ36526893
Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencingQ36540055
Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequencesQ36637273
Exploiting the defensive sugars of HIV-1 for drug and vaccine designQ36802333
Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodiesQ36884458
Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypesQ36960293
Low level viremia and high CD4% predict normal survival in a cohort of HIV type-2-infected villagersQ38906206
Genetic variability of human immunodeficiency virus type 2 C2V3 region within and between individuals from Bissau, Guinea-Bissau, West AfricaQ39340240
The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralizationQ39362853
Quantitation of human immunodeficiency virus type 2 DNA in peripheral blood mononuclear cells by using a quantitative-competitive PCR assayQ39446427
Immune-mediated positive selection drives human immunodeficiency virus type 1 molecular variation and predicts disease duration.Q39685744
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitutionQ40060900
Evolution of human immunodeficiency virus type 2 coreceptor usage, autologous neutralization, envelope sequence and glycosylationQ40349284
Humoral immunity and the evolution of HIV-2.Q43218253
HIV-2-infected patients survive longer than HIV-1-infected patients.Q43712041
CCR5 use by human immunodeficiency virus type 1 is associated closely with the gp120 V3 loop N-linked glycosylation siteQ45419807
Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture.Q45420512
Phylogenetic demonstration of two cases of perinatal human immunodeficiency virus type 2 infection diagnosed in adulthoodQ45524572
A statistical characterization of consistent patterns of human immunodeficiency virus evolution within infected patientsQ45557943
Widespread adaptive evolution in the human immunodeficiency virus type 1 genomeQ45710774
Serum immunoglobulin A (IgA)-mediated immunity in human immunodeficiency virus type 2 (HIV-2) infectionQ45724156
Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infectionQ45739618
Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral loadQ45743456
Small amino acid changes in the V3 loop of human immunodeficiency virus type 2 determines the coreceptor usage for CXCR4 and CCR5.Q45746519
Intrapatient Variability of the Human Immunodeficiency Virus Type 2 Envelope V3 LoopQ45788570
Proviral load and immune function in blood and lymph node during HIV-1 and HIV-2 infectionQ46908458
Long-term intrapatient viral evolution during HIV-2 infectionQ46977891
Adaptation in the env gene of HIV-1 and evolutionary theories of disease progressionQ47872743
Positive in vivo selection of the HIV-1 envelope protein gp120 occurs at surface-exposed regionsQ48078795
Evidence for negative selective pressure in HIV-2 evolution in vivoQ48148785
The emerging genetic diversity of HIV. The importance of global surveillance for diagnostics, research, and prevention.Q52312661
In vitro replication capacity of HIV-2 variants from long-term aviremic individualsQ56880140
N-Linked Glycosylation of the HIV Type-1 gp120 Envelope Glycoprotein as a Major Determinant of CCR5 and CXCR4 Coreceptor UtilizationQ56935643
Plasma Viral Load Threshold for Sustaining Intrahost HIV Type 1 EvolutionQ58415389
N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytesQ67701330
Autologous neutralizing antibodies prevail in HIV-2 but not in HIV-1 infectionQ70573580
Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infectionQ77296161
Mutation, fitness, viral diversity, and predictive markers of disease progression in a computational model of HIV type 1 infectionQ81270975
P407language of work or nameEnglishQ1860
P304page(s)78
P577publication date2008-09-08
P1433published inRetrovirologyQ15793508
P1476titleThe role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients
P478volume5

Reverse relations

cites work (P2860)
Q34062608A comparison of parallel pyrosequencing and sanger clone-based sequencing and its impact on the characterization of the genetic diversity of HIV-1.
Q37517645A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support
Q38717198Engineering broadly neutralizing antibodies for HIV prevention and therapy
Q33591409Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response
Q33809419Evolutionary and structural features of the C2, V3 and C3 envelope regions underlying the differences in HIV-1 and HIV-2 biology and infection
Q36651031HIV-2 and its role in conglutinated approach towards Acquired Immunodeficiency Syndrome (AIDS) Vaccine Development
Q33966596HIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients
Q37001043Isolation of a new HIV-2 group in the US.
Q58546281LOW-BIAS RNA SEQUENCING OF THE HIV-2 GENOME FROM BLOOD PLASMA
Q60917430Low Postseroconversion CD4 T-cell Level Is Associated with Faster Disease Progression and Higher Viral Evolutionary Rate in HIV-2 Infection
Q34039423Origin and epidemiological history of HIV-1 CRF14_BG.
Q34290973Potent and broadly reactive HIV-2 neutralizing antibodies elicited by a vaccinia virus vector prime-C2V3C3 polypeptide boost immunization strategy
Q35115656Thymic HIV-2 infection uncovers posttranscriptional control of viral replication in human thymocytes.
Q92547213Variation in Intra-individual Lentiviral Evolution Rates: a Systematic Review of Human, Nonhuman Primate, and Felid Species

Search more.